Supplementary Figure 5:
The efficacy of JAK inhibitors on JAK2 translocated and mutated cells per type of aberration. Leukemic (PDX or primary patient) cells were incubated for four days to indicated concentrations of momelotinib or ruxolitinib, after which viability was measured using an MTT assay. Sensitivity of exposed cells was calculated relative to vehicle treated controls. Individual samples were tested in duplicate. Data derived from samples with identical JAK2 lesions were grouped for analyses. 
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R683G PDX cells were exposed for four hours to vehicle control medium, 1.5 μM momelotinib or 0.75 μM ruxolitinib, after which (phosphorylated) TERF2-JAK2, PAX5-JAK2, JAK2, STAT1 and STAT5 levels were analyzed using western blot (25 μg lysate). Expression levels of phospho-proteins were quantified relative to total protein or loading control. Leukemic (PDX or primary patient) cells were pre-incubated for 1 hour without or with 25 ng/ml TSLP, after which they were exposed for four days to indicated concentrations of momelotinib or ruxolitinib. Viability was measured using an MTT assay. Sensitivity was calculated relative to vehicle treated controls. Individual samples were tested in duplicate. R683G cells were pre-incubated for 1 hour with or without 25 ng/ml TSLP, after which cells were exposed for four hours to vehicle control medium, 1.5 μM momelotinib or 0.75 μM ruxolitinib. Levels of (phosphorylated) JAK2, STAT1, STAT5, MEK1/2 and ERK1/2 were analyzed using western blot. Expression levels of phospho-proteins were quantified relative to total protein or loading control (α-Tubulin).
Supplementary Figure 10: Quantified expression levels western blots Figure 4. TERF2-JAK2 PDX cells were incubated for
four hours with or without 1.5 μM momelotinib or 0.75 μM ruxolitinib, after which cells were washed to remove the JAK inhibitors. Half of the cells were exposed for another 1.5 hours to 1.5 μM momelotinib or 0.75 μM ruxolitinib, whereas the other cells were incubated in vehicle control (Ctr) medium. Protein expression levels were examined by western blot (25 μg lysate). Expression levels of phosphoproteins were quantified relative to total protein.
Supplementary Figure 11: Accumulation of pJAK2
Y1007 results in a rebound effect of JAK2. (A) HEL cells were incubated with or without 1.5 μM momelotinib or 0.75 μM ruxolitinib for 4 hours, 24 hours, 48 hours, 72 hours and 96 hours, after which cells were lysed and protein expression levels were examined using western blot (25 μg lysate). (B) After 96 hours of exposure to JAK inhibitors (indicated by * in panel A), cells were washed in normal culture medium, to remove momelotinib and ruxolitinib. Subsequently, half of the cells were incubated with 1.5 μM momelotinib or 0.75 μM ruxolitinib for another 4 hours, or 24 hours, whereas the remaining cells were incubated in vehicle control (Ctr) medium. Protein expression levels were examined using western blot (25 μg lysate). 
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